Genmab A (GMAB) Enterprise Value (2023 - 2025)

Genmab A's Enterprise Value history spans 3 years, with the latest figure at -$1.7 billion for Q4 2025.

  • For Q4 2025, Enterprise Value fell 24.28% year-over-year to -$1.7 billion; the TTM value through Dec 2025 reached -$1.7 billion, down 24.28%, while the annual FY2025 figure was -$1.7 billion, 24.28% down from the prior year.
  • Enterprise Value reached -$1.7 billion in Q4 2025 per GMAB's latest filing, down from -$1.4 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.4 billion in Q4 2024 to a low of -$2.2 billion in Q4 2023.
  • Average Enterprise Value over 3 years is -$1.8 billion, with a median of -$1.7 billion recorded in 2025.
  • Peak YoY movement for Enterprise Value: soared 37.39% in 2024, then decreased 24.28% in 2025.
  • A 3-year view of Enterprise Value shows it stood at -$2.2 billion in 2023, then soared by 37.39% to -$1.4 billion in 2024, then fell by 24.28% to -$1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for GMAB's Enterprise Value are -$1.7 billion (Q4 2025), -$1.4 billion (Q4 2024), and -$2.2 billion (Q4 2023).